Haiwen & Partners is sought out by biotechnology, medical device, cosmetic and health food clients for its corporate, IP and regulatory expertise that tackles all aspects of issues that arise from the entire product life cycle. The team is led by Tina Wu, adept in licensing, regulatory and compliance work concerning clinical research, product development and licensing deals. Rui Feng excels in M&A, corporate and regulatory compliance, while IP specialist Frank Wang is noted for patent examination matters and IP litigation. Xiaobin Zhu focuses on private equity and venture capital investments. Wenzhen Dai is a key M&A lawyer in the medical sector.
Legal 500 Editorial commentary
Key clients
- New Frontier Group
- Wuxi Innovation Investment Group
- Jianxin Financial Asset Investment Co., Ltd.
- Agricultural Bank Financial Assets Investment Co., Ltd.
- ICBC Financial Asset Investment Co., Ltd.
- Bank of Communications Financial Assets Investment Co., Ltd.
- Boc Financial Assets Investment Co., Ltd.
- Beijing Guo Rui Zhong Xin Equity Investment Fund
- Nuvation Bio
- Qingdao Guoxin
- Genor Biopharma Holdings Limited
Work highlights
Assisting Zhiyuanbaimai (Hangzhou) Technology Co., Ltd. with minority equity investment project.
Assisting the Genor Biopharma merger with Edding Group through reverse takeover and share exchange.
Assisting New Frontier in the acquisition of HKIOC with Tens of Millions of Dollars, the largest healthcare M&A in HK in recent years.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Tina Wu
Other key lawyers
Rui Feng; Frank Wang; Wenzhen Dai; Xiaobin Zhu